← Leaderboards
Anne Messer
Intraimmune Therapies, Inc.
$3,722,627
Attributed
$3,910,808
Total exposure
6
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $605.4K · FY2006–12$1M$750K$500K$250K$0
'06
'07
'08
'09
'10
'11
'12
Funding mix
By agency
NIH$3,910,808 · 6
By mechanism
R01$1,802,023 · 1
R21$1,608,785 · 4
R42$500,000 · 1
Top collaborators
- Michael R Sierks2 shared
Others in their field
Top investigators on “Proteins”
- David Heimbrook · Leidos Biomedical Research, Inc.$354,061,551
- Randall J Bateman · Washington University$187,292,085
- Paul S. Aisen · Cognition Therapeutics, Inc.$175,382,342
- Reisa A. Sperling · Banner Health$145,046,481
- Barton F Haynes · Duke University$136,029,850
- Joseph L Goldstein · University Of Texas Sw Med Ctr/Dallas$102,433,280
Research focus
ProteinsToxic EffectNuclearProtein MisfoldingReagentS DiseaseMouse ModelNeuronsParkinson DiseasePrion DiseasesProtocols DocumentationImmunoglobulin FragmentsIn VivoAntibodiesDisease ModelHuntington DiseaseAlzheimer&AposNeurodegenerative DisordersCell ModelCellsGenerationsEngineeringCell LineLength
Grant awards (19)
Harnessing novel cell-penetrating antibodies for neuronal correction$219,027
R21 · FY2012 · NS · contact PI
Harnessing novel cell-penetrating antibodies for neuronal correction$182,965
R21 · FY2011 · NS · contact PI
Intrabodies as novel neurological therapeutics$344,879
R01 · FY2010 · NS · contact PI
Intrabodies as novel neurological therapeutics$374,074
R01 · FY2009 · NS · contact PI
Conformation-specific Single-chain Antibodies as Neurodegeneration Research Tools$199,968
R21 · FY2009 · NS
Intrabodies as novel neurological therapeutics$25,460
R01 · FY2009 · NS · contact PI
Intrabodies as novel neurological therapeutics$317,687
R01 · FY2008 · NS · contact PI
Conformation-specific Single-chain Antibodies as Neurodegeneration Research Tools$176,394
R21 · FY2008 · NS
Intrabodies as novel neurological therapeutics$77,841
R01 · FY2008 · NS · contact PI
Intrabodies as novel neurological therapeutics$33,478
R01 · FY2008 · NS · contact PI
Intrabodies as novel neurological therapeutics$313,970
R01 · FY2007 · NS · contact PI
Intrabodies as novel neurological therapeutics$314,634
R01 · FY2006 · NS · contact PI
Gene therapy vectors for pediatric brain disease$173,571
R21 · FY2003 · NS
Intrabody Therapy of Parkinson's Disease$149,187
R21 · FY2003 · NS
Gene therapy vectors for pediatric brain disease$182,933
R21 · FY2002 · NS
Intrabody Therapy of Parkinson's Disease$145,653
R21 · FY2002 · NS
INTRABODY CONTROL OF EXPANDED-REPEAT NEURODEGENERATION$250,000
R42 · FY2001 · NS
Gene therapy vectors for pediatric brain disease$179,087
R21 · FY2001 · NS
INTRABODY CONTROL OF EXPANDED-REPEAT NEURODEGENERATION$250,000
R42 · FY2000 · NS